Deferiprone does not protect against chronic anthracycline cardiotoxicity in vivo.

Full Abstract

Anthracycline cardiotoxicity ranks among the most severe complications of cancer chemotherapy. Although its pathogenesis is only incompletely understood, "reactive oxygen species (ROS) and iron" hypothesis has gained the widest acceptance. Besides dexrazoxane, novel oral iron chelator deferiprone has been recently reported to afford significant cardioprotection in both in vitro and ex vivo conditions. Therefore, the aim of this study was to assess whether deferiprone 1) has any effect on the anticancer action of daunorubicin and 2) whether it can overcome or significantly reduce the chronic anthracycline cardiotoxicity in the in vivo rabbit model (daunorubicin, 3 mg/kg i.v., weekly for 10 weeks). First, using the leukemic cell line, deferiprone (1-300 microM) was shown not to blunt the antiproliferative effect of daunorubicin. Instead, in clinically relevant concentrations (>10 microM), deferiprone augmented the antiproliferative action of daunorubicin. However, deferiprone (10 or 50 mg/kg administered p.o. before each daunorubicin dose) failed to afford significant protection against daunorubicin-induced mortality, left ventricular lipoperoxidation, cardiac dysfunction, and morphological cardiac deteriorations, as well as an increase in plasma cardiac troponin T. Hence, this first in vivo study changes the current view on deferiprone as a potential cardioprotectant against anthracycline cardiotoxicity. In addition, these results, together with our previous findings, further suggest that the role of iron and its chelation in anthracycline cardiotoxicity is not as trivial as originally believed and/or other mechanisms unrelated to iron-catalyzed ROS production are involved.

Learn Faster Today Improve your study skills

Author information

Author/s: Popelová, Olga (O); Sterba, Martin (M); Simunek, Tomás (T); Mazurová, Yvona (Y); Guncová, Ivana (I); Hroch, Milos (M); Adamcová, Michaela (M); Gersl, Vladimír (V);

Affiliation: Department of Pharmacology, Charles University in Prague, Faculty of Medicine in Hradec Králové, Simkova 870, 500 38 Hradec Králové, Czech Republic. popelovao@lfhk.cuni.cz

Journal and publication information

Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

Journal: The Journal of pharmacology and experimental therapeutics (J Pharmacol Exp Ther), published in United States. (Language: eng)

Reference: 2008-Jul; vol 326 (issue 1) : pp 259-69

Dates: Created 2008/06/19; Completed 2008/07/30;

PMID: 18434588, status: MEDLINE (last retrieval date: 11/6/2008)

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article (including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Animals
Anthracyclines - administration & dosage; antagonists & inhibitors; toxicity
Antineoplastic Agents - therapeutic use; toxicity
Cardiotonic Agents - therapeutic use; toxicity
Cell Proliferation - drug effects
Daunorubicin - antagonists & inhibitors

HL-60 Cells
Heart Diseases - chemically induced; mortality; pathology
Humans
Male
Pyridones - therapeutic use
Rabbits

Associated Chemicals: Anthracyclines (0) ; Antineoplastic Agents (0) ; Cardiotonic Agents (0) ; Pyridones (0) ; Daunorubicin (20830-81-3) ; deferiprone (30652-11-0)

These are the highest related articles currently in the database:

See 100+ related articles.